ArticleMedicine in drug discovery2019
Cells and cell derivatives as drug carriers for targeted delivery.
Article in Medicine in drug discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Inhalable bioadhesive barrier for lung protection and clearance of fine particulate matter.Bioactive materials · 2026Article
- From Adipose Tissue to Cardiac Repair: Extracellular Vesicles in Cardiovascular Regeneration.Journal of cellular and molecular medicine · 2026Review
- Genetically engineered human cell-based microrobots for selective cancer cell death.Science advances · 2026Article
- From bench to bedside: the promise and roadblocks of extracellular vesicle therapeutics.Theranostics · 2026Review
- Repair of female reproductive function by GDF-9-overexpressing extracellular vesicles via ACVR1B/SMAD2 regulation in ovarian granulosa.Science advances · 2025Article
- Article
- Nanotechnology-Based Drug Delivery Systems, 2nd Edition.Pharmaceutics · 2025Article
- Personalized peripheral vascular interventional embolization for tumor: tailoring treatment to improve outcomes.Frontiers in medicine · 2025Review
- Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data.Scientific reports · 2024Article
- Intelligent berberine-loaded erythrocytes attenuated inflammatory cytokine productions in macrophages.Scientific reports · 2024Article
- Extracellular vesicle mimetics as delivery vehicles for oligonucleotide-based therapeutics and plasmid DNA.Frontiers in bioengineering and biotechnology · 2024Article
- Organic and Biogenic Nanocarriers as Bio-Friendly Systems for Bioactive Compounds' Delivery: State-of-the Art and Challenges.Materials (Basel, Switzerland) · 2023Review
- Investigations on Cellular Uptake Mechanisms and Immunogenicity Profile of Novel Bio-Hybrid Nanovesicles.Pharmaceutics · 2022Article
- Bacteria and cells as alternative nano-carriers for biomedical applications.Expert opinion on drug delivery · 2022Review
- Macrophage-derived exosomes mediate silica-induced pulmonary fibrosis by activating fibroblast in an endoplasmic reticulum stress-dependent manner.Journal of cellular and molecular medicine · 2021Article
- Review
- Chronicles of Nanoerythrosomes: An Erythrocyte-Based Biomimetic Smart Drug Delivery System as a Therapeutic and Diagnostic Tool in Cancer Therapy.Pharmaceutics · 2021Review
- Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019.Advanced nanobiomed research · 2021Article
- Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.Advanced therapeutics · 2021Review
- Exosome therapeutics for lung regenerative medicine.Journal of extracellular vesicles · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
For over a century, researchers have focused on how to optimize drug delivery. Systemic administration means that the drug becomes dilute and has the potential to diffuse to all tissues, which is only until the immune system steps in and rapidly clears it from blood circulation. Drug carriers are the solution for amplifying the intended effect and diminishing side effects. With drug carriers, tissue-specific drug delivery and controlled drug release is possible. Thus far, both synthetic and non-synthetic carriers exist. However, due to the numerous limitations of synthetic carriers, science has begun to concentrate on using live cells and cell-derivatives as drug carriers. The most problematic shortcomings of synthetic carriers are their limited biocompatibility and biodegradability. Most synthetic carriers are cytotoxic or induce immune responses. Moreover, synthetic carriers typically depend on passive diffusion and risk phagocytosis, further reducing their impact. On the other hand, live-cell carriers and their derivatives usually have a targeting mechanism and drug release is controlled, increasing the efficiency with which a drug accumulates and acts on a tissue. Still, both types of carriers face similar problems, including achieving high loading capacity, maintaining drug quality, efficiently accumulating in the target tissue, and minimizing side effects. This review aims to elucidate the advantages and disadvantages of each popular cell or cell-derived carrier and to spotlight novel solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.